StemCell Technologies Canada Inc.

The present application is directed to a composite material comprising a core that is responsive to a magnet or a magnetic field, surrounded by a polymer that has been chemically modified to spontaneously bind and assemble a dense corona of fluorescent quantum dots, which is then over-coated with another layer of modified polymer that can be bound by an antibody complex for targeting specific antigens. Methods of preparing and using this material for the detection and quantification of target antigens is also included in the application.

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and/or for modulating an immune response in an individual with an HPV-associated disease.

A microfluidic chip for causing the delivery of a payload to a cell comprises a plurality of constrictions configured to allow a cell suspension to flow through one or more of the plurality of constrictions from a first fluid flow region to a second fluid flow region within the microfluidic chip, wherein a cross-sectional width of each of the plurality of constrictions is less than a diameter of cells in the cell suspension, such that membranes of the cells are perturbed when passing through the constrictions such that a payload is able to pass through the perturbed cell membranes, and wherein a quotient of a cross-sectional area over a cross-sectional perimeter of each of the plurality of constrictions is greater than greater than or equal to 0.5 μm.

This disclosure relates to laboratory devices and systems. methods of use, and methods of manufacture. Laboratory devices of this disclosure include a chamber or receptacle, and may also include one or more ports fluidically connected to the chamber. Thus. laboratory devices may be closed systems, and may therefore be particularly amenable to cell culture applications. In some embodiments. laboratory devices may include a gas permeable membrane. Liquid filling of and withdrawal from a chamber/receptacle of a laboratory device of this disclosure may be facilitated by a lid or adapter feature that imparts a tilt or angle to the chamber.

The present disclosure provides isolated polynucleotides comprising multiple coding regions that are linked. In some aspects, a polynucleotide comprises at least a first coding region encoding a first antigen and a second coding region encoding a second antigen, wherein the first antigen and the second antigen are not the same, and wherein the first coding region and the second coding region are linked. The present disclosure also relates to the use of such polynucleotides to express multiple antigens in a cell and to induce multi-antigen-specific immune response in vivo.

The present application provides formulations of enhanced antigen presenting cells (“enhanced APCs”), wherein the formulation comprises: the enhanced APCs comprising an antigen (e.g., a human papillomavirus (HPV) antigen) and one or more of the following: cryopreservation medium, hypothermic preservation medium, and human serum albumin. Also provided herein are methods of producing such formulations and the enhanced APCs.

The present application provides enhanced APCs for treating HPV-associated cancers. The enhanced APCs are capable of activating T cells in an HLA agnostic manner and are derived from input APCs in which at least one nucleic acid encoding an HPV antigen has been delivered intracellularly. In some aspects, the enhanced APCs are administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1/PD-L1 and/or an antagonist of CTLA-4.

Disclosed herein are media, kits, and methods for differentiating mammalian progenitor cells to a downstream lineage of cells. Embodiments of disclosed media, methods and kits may be used to differentiate mammalian progenitor cells to tenocytes or tenocyte-like cells, or chondrocytes or chondrocyte-like cells.

The present application provides TILs comprising agents that enhance activity and/or proliferative capacity of the TILs, methods of manufacturing such TILs, and methods of using such modified TILs for enhancing an immune response.

The present application provides activating antigen carriers (AACs) for treating HPV-associated cancers. AACs are derived from anucleate cells in which at least one antigen and an adjuvant have been delivered intracellularly. In some embodiments, the AAC is administered in combination with a checkpoint inhibitor such as a CTLA4 antagonist and/or a PD-1/PD-L1 agonist.